Latest Balance Sheet News

Global Lithium Resources has sold its entire 264 million shareholding in Kairos Minerals for $7.1 million, boosting its cash reserves to $21.8 million. The company will now focus these funds on advancing its flagship Manna Lithium Project.

Altamin Limited has launched a $6.46 million accelerated entitlement offer, strongly supported by its largest shareholder, to fund development at its Lazio and Gorno projects. The capital raise aims to advance exploration and maintain operational readiness amid strategic options for Gorno.

Reece Limited has announced an off-market share buy-back targeting $250 million, with flexibility up to $400 million, offering shareholders a premium price range between $11.00 and $13.00 per share. This move aims to return excess capital while preserving financial flexibility for future growth.

Hastings Technology Metals and Wyloo have formalised their joint venture for the Yangibana Rare Earths Project, with Wyloo taking a 60% stake and cancelling A$123 million in exchangeable notes, significantly de-risking the project and reducing Hastings’ funding burden.

HealthCo Healthcare & Wellness REIT has collected all outstanding rent from Healthscope and extended a rent deferral to support the ongoing sale process, while suspending distributions to preserve liquidity.

Activeport Group Ltd has successfully raised $6.68 million through a two-tranche placement, positioning the company to accelerate its software development and target cash flow positivity in FY26.

XPON Technologies announces a significant leadership reshuffle with founder Matt Forman stepping down as CEO due to health reasons, while Mark Simari assumes the role of Executive Chair amid strategic growth initiatives.

Resolution Minerals Ltd has successfully raised $25.1 million through a heavily supported placement, positioning itself to advance its Horse Heaven Project in Idaho and prepare for a NASDAQ listing.

Highfield Resources has requested a voluntary suspension of its shares on the ASX to complete a capital raising, with trading expected to resume by 23 September 2025.

Neurizon Therapeutics has raised $5 million through an institutional placement to advance its lead ALS drug candidate NUZ-001 into a pivotal clinical trial, pending FDA clearance. The capital injection also supports manufacturing and pre-clinical development efforts.

Robex Resources has moved up the expiry date of its 2024 Warrants to October 2025 after its share price hit a key threshold, potentially unlocking C$147 million to fund its Kiniero Gold Project in Guinea.

Nexion Group has amended its sale agreement with Pier DC to include cancellation of an increased $1.75 million in Convertible Notes, reflecting recent fundraising. This adjustment marks a key step in the divestment of its Networks and Telecom units.